Overview
Hepatic amyloidosis involves the deposition of amyloid proteins in the liver, leading to organ dysfunction. This condition can be categorized into primary (often hereditary) and secondary forms, with secondary amyloidosis often associated with chronic inflammatory diseases 1.Diagnosis
Immunohistochemical Staining: Use anti-human P component for sensitive detection of amyloid deposits 1.
Congo Red Staining: Essential for confirming amyloid presence through characteristic birefringence under polarized light.
Histochemical Analysis: Differentiate hepatic amyloid from cerebral or systemic types based on unique characteristics 1.Management
Primary Amyloidosis: Treatment focuses on underlying genetic conditions and may include organ transplantation in severe cases.
Secondary Amyloidosis: Manage underlying inflammatory disease (e.g., with corticosteroids, immunosuppressants) to slow amyloid deposition 1.
Supportive Care: Includes monitoring liver function, managing symptoms, and addressing complications like portal hypertension 1.Special Populations
Elderly: Higher incidence of amyloid deposits noted, with increased frequency starting in the 3rd decade and reaching 73% in the 5th decade 1.Key Recommendations
Utilize a combination of Congo red staining and anti-human P component immunohistochemistry for accurate detection of hepatic amyloid deposits (Evidence: Moderate) 1.
Prioritize treatment of the underlying inflammatory condition in secondary hepatic amyloidosis to mitigate progression (Evidence: Moderate) 1.
Regular monitoring of liver function is crucial in elderly patients due to increased prevalence of amyloid deposits (Evidence: Expert opinion) 1.References
1 Tashima T, Kitamoto T, Tateishi J, Ogomori K, Nakagaki H. Incidence and characterization of age related amyloid deposits in the human anterior pituitary gland. Virchows Archiv. A, Pathological anatomy and histopathology 1988. link